Fexofenadine brain exposure and the influence of blood-brain barrier P-glycoprotein after fexofenadine and terfenadine administration

Drug Metabolism and Disposition

Volumn 37, Issue 3, 2009, Pages 529-535

  Zhao, Rong ^a   Kalvass, J Cory ^b   Yanni, Souzan B ^a   Bridges, Arlene S ^a   Pollack, Gary M ^a  

^a UNIVERSITY OF NORTH CAROLINA   (United States)

^b ELI LILLY AND COMPANY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FEXOFENADINE; GLYCOPROTEIN P; TERFENADINE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BLOOD BRAIN BARRIER; BRAIN HOMOGENATE; BRAIN METABOLISM; CONTROLLED STUDY; DRUG BRAIN LEVEL; DRUG DISPOSITION; DRUG HYDROXYLATION; DRUG PENETRATION; DRUG UPTAKE; MATHEMATICAL MODEL; MOUSE; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; BLOOD-BRAIN BARRIER; BRAIN; MICE; P-GLYCOPROTEIN; TERFENADINE;

MURINAE; MUS;

EID: 61449099555     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.107.019893     Document Type: Article

References (35)

1. Begley DJ (2003) Understanding and circumventing the blood-brain barrier. Acta Paediatr Suppl 92:83-91.
2. Brodie BB, Kurz H, and Schanker LS (1960) The importance of dissociation constant and lipid-solubility in influencing the passage of drugs into the cerebrospinal fluid. J Pharmacol Exp Ther 130:20-25.
3. Brown RP, Delp MD, Lindstedt SL, Rhomberg LR, and Beliles RP (1997) Physiological parameter values for physiologically based pharmacokinetic models. Toxicol Ind Health 13:407-484.
4. Chen C, Hanson E, Watson JW, and Lee JS (2003) P-glycoprotein limits the brain penetration of nonsedating but not sedating Hl-antagonists. Drug Metab Dispos 31:312-318.
5. Cvetkovic M, Leake B, Fromm MF, Wilkinson GR, and Kim RB (1999) OATP and P-glycoprotein transporters mediate the cellular uptake and excretion of fexofenadine. Drug Metab Dispos 27:866-871.
6. Dagenais C, Rous selle C, Pollack GM, and Scherrmann JM (2000) Development of an in situ mouse brain perfusion model and its application to mdrla P-glycoprotein-deficient mice. J Cereb Blood Flow Metab 20:381-386.
7. Dagenais C, Zong J, Ducharme J, and Pollack GM (2001) Effect of mdrla P-glycoprotein gene disruption, gender, and substrate concentration on brain uptake of selected compounds. Pharm Res 18:957-963.
8. Fenstermacher JD, Blasberg RG, and Patlak CS (1981) Methods for Quantifying the transport of drugs across brain barrier systems. Pharmacol Ther 14:217-248.
9. Graff CL and Pollack GM (2004) Drug transport at the blood-brain barrier and the choroid plexus. Curr Drug Metab 5:95-108.
10. Hagemeyer CE, Rosenbrock H, Ditter M, Knoth R, and Volk B (2003) Predominantly neuronal expression of cytochrome P450 isoforms CYP3A11 and CYP3A13 in mouse brain. Neuroscience 117:521-529.
11. Holleran JL, Fourcade J, Egorin MJ, Eiseman JL, Parise RA, Musser SM, White KD, Covey JM, Forrest GL, and Pan SS (2004) In vitro metabolism of the phosphatidylinositol 3-kinase inhibitor, wortmannin, by carbonyl reductase. Drug Metab Dispos 32:490-496.
12. Kalvass JC and Maurer TS (2002) Influence of nonspecific brain and plasma binding on CNS exposure: implications for rational drug discovery. Biopharm Drug Dispos 23:327-338.
13. Kalvass JC, Maurer TS, and Pollack GM (2007a) Use of plasma and brain unbound fractions to assess the extent of brain distribution of 34 drugs: comparison of unbound concentration ratios to in vivo P-glycoprotein efflux ratios. Drug Metab Dispos 35:660-666.
14. Kalvass JC, Olson ER, Cassidy MP, Selley DE, and Pollack GM (2007b) Pharmacokinetics and pharmacodynamics of seven opioids in P-gp-competent mice: assessment of unbound brain EC50 and correlation of in vitro, preclinical, and clinical data. J Pharmacol Exp Ther 323:346-355.
15. Kalvass JC and Pollack GM (2007) Kinetic considerations for the quantitative assessment of efflux activity and inhibition: implications for understanding and predicting the effects of efflux inhibition. Pharm Res 24:265-276.
16. Ling KH, Leeson GA, Burmaster SD, Hook RH, Reith MK, and Cheng LK (1995) Metabolism of terfenadine associated with CYP3A(4) activity in human hepatic microsomes. Drug Metab Dispos 23:631-636.
17. Liu X and Chen C (2005) Strategies to optimize brain penetration in drug discovery. Curr Opin Drug Discov Devel 8:505-512.
18. Liu X, Smith BJ, Chen C, Callegari E, Becker SL, Chen X, Cianfrogna J, Doran AC, Doran SD, Gibbs JP, et al. (2005) Use of a physiologically based pharmacokinetic model to study the time to reach brain equilibrium: an experimental analysis of the role of blood-brain barrier permeability, plasma protein binding, and brain tissue binding. J Pharmacol Exp Ther 313:1254-1262.
19. Liu X, Tu M, Kelly RS, Chen C, and Smith BJ (2004) Development of a computational approach to predict blood-brain barrier permeability. Drug Metab Dispos 32:132-139.
20. Mahar Doan KM, Wring SA, Shampine LJ, Jordan KH, Bishop JP, Kratz J, Yang E, Serabjit-Singh CJ, Adkison KK, and Polli JW (2004) Steady-state brain concentrations of antihistamines in rats: interplay of membrane permeability, P-glycoprotein efflux and plasma protein binding. Pharmacology 72:92-98.
21. Markham A and Wagstaff AJ (1998) Fexofenadine. Drugs 55:269-274;
22. discussion 275-266.
23. Mattila MJ and Paakkari I (1999) Variations among non-sedating antihistamines: are there real differences? Eur J Clin Pharmacol 55:85-93.
24. Meyer RP, Gehlhaus M, Knoth R, and Volk B (2007) Expression and function of cytochrome p450 in brain drug metabolism. Curr Drug Metab 8:297-306.
25. Meyer RP, Hagemeyer CE, Knoth R, Kaufmann MR, and Volk B (2006) Anti-epileptic drug Phenytoin enhances androgen metabolism and androgen receptor expression in murine hippocampus. J Neurochem 96:460-472.
26. Miksys SL and Tyndale RF (2002) Drug-metabolizing cytochrome P450s in the brain. J Psychiatry Neurosci 27:406-415.
27. Obradovic T, Dobson GG, Shingaki T, Kungu T, and Hidalgo U (2007) Assessment of the first and second generation antihistamines brain penetration and role of P-glycoprotein. Pharm Res 24:318-327.
28. Petri N, Tannergren C, Rungstad D, and Lennernas H (2004) Transport characteristics of fexofenadine in the Caco-2 cell model. Pharm Res 21:1398-1404.
29. Polli JW, Baughman TM, Humphreys JE, Jordan KH, Mote AL, Salisbury JA, Tippin TK, and Serabjit-Singh CJ (2003) P-glycoprotein influences the brain concentrations of cetirizine (Zyrtec), a second-generation non-sedating antihistamine. J Pharm Sci 92:2082-2089.
30. Rudick RA, Zirretta DK, and Herndon RM (1982) Clearance of albumin from mouse subarachnoid space: a measure of CSF bulk flow. J Neurosci Methods 6:253-259.
31. Schinkel AH, Smit JJ, van Tellingen O, Beijnen JH, Wagenaar E, van Deemter L, Mol CA, van der VaIk MA, Robanus-Maandag EC, and te Riele HP (1994) Disruption of the mouse mdrla P-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs. Cell 77:491-502.
32. Strobel HW, Thompson CM, and Antonovic L (2001) Cytochromes P450 in brain: function and significance. Curr Drug Metab 2:199-214.
33. Summerfield SG, Stevens AJ, Cutler L, del Carmen Osuna M, Hammond B, Tang SP, Hersey A, Spalding DJ, and Jeffrey P (2006) Improving the in vitro prediction of in vivo central nervous system penetration: integrating permeability, P-glycoprotein efflux, and free fractions in blood and brain. J Pharmacol Exp Ther 316:1282-1290.
34. Tahara H, Kusuhara H, Fuse E, and Sugiyama Y (2005) P-glycoprotein plays a major role in the efflux of fexofenadine in the small intestine and blood-brain barrier, but only a limited role in its biliary excretion. Drug Metab Dispos 33:963-968.
35. Takasato Y, Rapoport SI, and Smith QR (1984) An in situ brain perfusion technique to study cerebrovascular transport in the rat. Am J Physiol 247:H484-H493.